Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

Inclusion criteria

• Post menopausal females
• Surgically sterile females
• Body Mass Index between 18-37
• Subjects with Clcr greater than 80 mL/min
• Subjects with Clcr 50 to 80 mL/min
• Subjects with Clcr 30 to 50 mL/min
• Clcr less than 30 mL/min but not on dialysis
• Subjects must test negative for HIV
• Subjects must test negative for drugs of abuse at screening

Exclusion criteria

All Subjects :

• Concomitant Medication: Treatment with CYP3A4 inducers, such as rifampin and St. John's Wort within 14 days of Day 1 until they leave the clinic on Day 7
• Donation of blood within 30 days of Day 1
• Recent participation in an investigational drug study during which active medication was given within 30 days of Day 1
• History of gastrointestinal disorder that could result in incomplete absorption of study drug
• Malignancy
• Significant neurologic or psychiatric disorders
• History of drug or alcohol abuse in year prior to screening for this trial, or current intake or >14 standard alcoholic drinks per week
• Prior history of epilepsy or other seizure disorders
• Known hypersensitivity to inhibitors of raf kinase or VEGFR-2
• Females of child-bearing potential
• Smoking > 10 cigarettes/day or equivalent
• Excessive consumption (more than five 8-oz. cups/day) of coffee or caffeine

Healthy Volunteer:

• Existing failure of a major organ system, or a medical disorder that would impair the subject's ability to complete the study (in the opinion of the investigator or the sponsor), eg history of blood coagulation disorders
• Hematocrit value < 34% in the control group at screening

Renal Impairment Groups:

• Existing failure of a major organ system or a medical disorder (other than the target disease) which would impair the subject's ability to complete the study (in the opinion of the investigator or the sponsor)
• Concomitant Medication: Renal impairment subjects taking phosphate binders, ion exchange resins and/or iron supplements may take them with their meals, but must withhold them on the morning of Day 1 (dosing day) until after their 4 hour post-dose tests and procedures are performed.
• Myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angiography within 6 months of Day 1; unstable angina; uncontrolled significant hypertension within 3 months of Day 1; cerebral vascular accident or transient ischemic attack within 12 months of Day 1
• Subjects with hypertension who have had a medication or dose change within one week of Day 1
• Subjects requiring dialysis
• Subjects with kidney transplants
• Liver transaminase (AST, ALT) greater than 5 times the ULN at screening; any active liver disease or unexplained or persistent elevations in liver function tests
• Hematocrit value < 24% in the renal impaired groups